Close Menu

NEW YORK – Ayala Pharmaceuticals and ArcherDX said today they will work together to develop companion diagnostics that can gauge whether cancer patients have Notch-activating genetic mutations and fusions and will respond to certain targeted drugs.  

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.